Bubs Australia Limited (ASX:BUB) Wins Arbitration Awards
Bubs Australia Limited (ASX:BUB) secures $22.9M and $3.6M arbitration awards against Alpha Group subsidiaries.
Bubs Australia Limited (ASX:BUB) secures $22.9M and $3.6M arbitration awards against Alpha Group subsidiaries.
Paradigm Biopharmaceuticals (ASX:PAR) announces the launch of its Phase 3 trial for knee osteoarthritis and the receipt of a $6.3 million R&D tax refund.
Donaco International (ASX:DNA) announces Q3 FY2025 results and a share acquisition Scheme Implementation Deed to strengthen its cash position.
PYC Therapeutics (ASX:PYC) extends cash runway to over $200m and advances polycystic kidney disease program in Q1 2025.
Atomo Diagnostics Limited (ASX:AT1) completes a $3.1 million capital raise and announces a board restructure to enhance operational efficiency and drive growth.
PWR (ASX:PWH) announces the temporary leave of its Managing Director and the appointment of Matthew Bryson as Acting CEO.
Dreadnought Resources Ltd (ASX:DRE) closes its Share Purchase Plan, raising $1.73M with strong shareholder support.
WiseTech Global (ASX:WTC) updates executive chair agreement and shares progress on CEO succession planning.
360 Capital Group (ASX:TGP) announces an off-market buy-back of up to 15.4% of its securities at $0.65 per security.
Waypoint REIT (ASX:WPR) announces a $50 million buyback and expansion of OTR conversions with Viva Energy to boost shareholder value.